

REMARKS

Claims 21, 25, 31, 38, 39 and 40 are currently amended. Reconsideration of the Application is requested in light of the amendments above and remarks below.

I: Prior Election

Applicants would like to thank the Examiner for rescinding the requirements for restriction between Groups 1, 4 and 5 in the communication mailed 8 November 2007 and examining claims 21-32 and 34-40. Applicants reserve the right to file additional applications on other identified groups.

II: Objections to the Specification

a. Hyperlinks

Applicants have amended the Application to make clear that the allegedly embedded hyperlinks are merely references to web pages for the reference of the reader. For example, Applicants removed any underlined language common to hyperlinks and removed the reference to "http://". Reconsideration is urged.

b. Sequence Listings

Applicants have amended the specification to include references to SEQ ID NOS. Reconsideration is urged. Applicants note that the rejection related to a "Figure Description" starting at page 19 and 21, appears to be in error as no additional sequences without SEQ ID NOS were identified by Applicants in review of the specification. Clarification is urged.

III: Objections to the Claims

The improper "s" in "claims 31" is removed. Reconsideration is urged.

IV: Provisional Double Patenting Rejection

Finally, under sections 804 and 822.01 of the Manual of Patent Examining Procedures, if a provisional double patenting rejection in one application is the only rejection remaining in that application, that rejection should be withdrawn and the provisional double patenting rejection in the other application be converted into a double patenting rejection. In accordance with this practice, Applicants request that the

obviousness-type double patenting rejection based on U.S. Application Nos. 10/560,224 be withdrawn in the present application.

V: Rejections pursuant to 35 U.S.C. 112

The Examiner has made various rejections pursuant to 35 U.S.C. 112. All independent claims are currently amended in response to all rejections pursuant 35 U.S.C. 112. Reconsideration is urged.

VI. Conclusion

In view of the above, it is respectfully submitted that all claims are in condition for allowance. Early action to that end is respectfully requested. The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: July 14, 2008

/Michael W Krenicky Reg. # 45411/
Michael Krenicky Reg. No. 45,411
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097